<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148820</url>
  </required_header>
  <id_info>
    <org_study_id>2019/D/789</org_study_id>
    <nct_id>NCT04148820</nct_id>
  </id_info>
  <brief_title>One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease</brief_title>
  <acronym>ONCE</acronym>
  <official_title>One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease: An Open Label, Randomized, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ischemic heart disease are often treated with multiple cardiovascular agents,
      including aspirin, statins, ezetimibe, Angiotensin Converting Enzyme (ACE) inhibitors or
      beta-blockers.

      Uncertainty about the optimal timing and clinical implications of administration of
      cardiovascular drugs still persists.

      The investigators will perform a pilot randomized trial to evaluate the efficacy and safety
      of a one daily administration of multiple drugs vs. twice daily administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ischemic heart disease are often treated with multiple cardiovascular agents,
      including aspirin, statins, ezetimibe, Angiotensin Converting Enzyme (ACE) inhibitors or beta
      blockers.

      These drugs are usually given at different timetables. Recent investigations, however, have
      demonstrated that adherence to medical treatment is significantly greater if a one daily
      strategy is adopted.

      Uncertainty about the optimal timing and clinical implications of administration of
      cardiovascular drugs still persists.

      The investigators will perform a pilot randomized trial to evaluate the efficacy and safety
      of a one daily administration of multiple drugs vs. twice daily administration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized into two parallel groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Outcome Event (MACE)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The time to final occurrence of cardiovascular death, non-fatal myocardial infarction, ischemic stroke or ischemia-driven revascularization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Once daily drug administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given cardiovascular drugs once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily drug administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given cardiovascular drugs twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin, Atorvastatin, Perindopril</intervention_name>
    <description>Cardiovascular drugs will be administered all together every day at the same time</description>
    <arm_group_label>Once daily drug administration</arm_group_label>
    <arm_group_label>Twice daily drug administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Ischemic heart disease, willing to participate, compliance to medical therapy

        Exclusion Criteria:

        Patients with acute coronary syndrome; pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Marazzi</last_name>
    <role>Study Director</role>
    <affiliation>San Raffaele Pisana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Pelliccia</last_name>
    <phone>+390633062615</phone>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Raffaele Pisana</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza University</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

